Yahoo Finance

Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours

Oslo, Norway, 16 December 2025– Zelluna (OSE: ZLNA), a company developing off-the-shelf cell therapies for cancer, today announced the publication of preclinical data for its lead candidate, ZI-MA4-1, ...
Yahoo Finance

Zelluna Receives Positive MHRA Feedback and Strengthens UK Clinical Strategy for ZI-MA4-1 Paving the Way for First-in-Human Trials in the UK

On track to file CTA by year end 2025, with plan to dose first patients and deliver initial data in 2026 Planned UK trial to be led by Prof. Fiona Thistlethwaite at The Christie NHS Foundation Trust, ...
PharmiWeb

Zelluna Reaches Major Milestone with Manufacturing Process Established in Preparation for Clinical Entry of ZI-MA4-1, its Novel TCR-NK Therapy Targeting Solid Tumours

Zelluna Reaches Major Milestone with Manufacturing Process Established in Preparation for Clinical Entry of ZI-MA4-1, its Novel TCR-NK Therapy Targeting Solid Tumours Oslo, Norway, 22 April 2025 – ...
BioWorld

Zelluna’s ZI-MA4-1 gains UK CTA clearance for solid tumors

Zelluna ASA has received approvals from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) and research ethics committee for its clinical trial application (CTA) for ZI-MA4-1, ...
Finanznachrichten

Zelluna ASA: Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours

Strong preclinical data support planned clinical trial initiation in 2026 Oslo, Norway, 16 December 2025- Zelluna (OSE: ZLNA), a company developing off-the-shelf cell therapies for cancer, today ...